Yep, as a matter of fact I added at the beginning of the week

Yesterday they said this in their earnings report:

Less than a month ago enrollment looked like it was proceeding. All these small bios have crapped out again

We have been trading below cash for some time now.  Market is interested in future prospects, and right now can project that cash goes to a miniscule amount before trajectory can be reversed by increased sales. Market can stay irrational for a very long time.  

If you like the stock price where it is, have no fear because after a RS it will come right back to where it is now. 

Why did this turn around today?  Passage of kidney bill increasing chance?

Companies initiate "strategic reviews" to investigate options including sale interest. Amarin must be using the "top secret" method of trying to sell the company.

Usually all this partnering is not conducive to a sell, but I am glad that they have not partnered the biggies: the U.S. and Europe. So still holding out hope.

Berg really didn't answer and just danced around the question about sale of the company. Disappointing

Filed deadline extension/

Disappointed that the Spanish guy emphasized Vazkepa being used for a niche of patient with high triglycerides. R-I showed benefits no matter the trig levels.

Oops, should be "why Amarin did NOT fall in behind...." Too early for me I guess.

For sure.  Thinking about the whole thing I am befuddled and stupified as to why Amarin did fall in behind Marjac's and North's endeavor.  That would have been our best and easiest path to righting this wrong.  With Amarin onboard it would have obviated the only thing the judges used to rule against them. 

Thanks North. Are you saying that the FTC (or possibly w/ DOJ) is or is planning to investigate Hikma/Dr.Reddy? Or simply explaining what could happen if the FTC did decide to investigate them?

Congrats Sleven. Filling up on shares over the past while has got my bag overflowing. Let's hope we all ultimately make out on this deal. I will have to get up bright and early tomorrow (well it won't be bright but rather dark at 5:00 am PST) to listen in.

In the Missouri Independent a month ago, a story about senators urging more investigation into PBMs getting more involved in what drugs we will be able to get:

https://missouriindependent.com/2024/10/09/senators-demand-another-antitrust-investigation-into-pharmacy-middlemen/

Congrats to your man Thune.

We won't know what they will present until they present it. Then you can bash.

So I am not real sharp on this type of stuff, but an institution buying would report on a 13f by the deadline, but wouldn't an insider like Denner have to report within 2 days of the purchase on a Form 4?

Pharmacydude over on ST has a post commenting on tomorrow's conference. He is suggesting that it will be basically a dog and pony show to try to firm up the stock price but if there is nothing of substance to the conference it may have the reverse effect showing desperation. He makes a good point about management not proceeding with buying shares but urging us to do so.

Nice.  I was once asked for my preference between France and Italy, and although I personally would not mind either I feel a bit more comfortable in France, only because I speak the language.  Crazy since my Mom was Italian. 

Yep, when I see those damn commercials, they always remind me that I screwed up when I didn't move to France upon retirement. 

That's fine but Amarin is going to have to be much more attractive to garner any interest. It is too soon, as we need to get a number of things in order. More reimbursement decisions in ROW (positive ones) and more of an idea of what is happening with the U.S. market, and any new possible formulations to bring to market.

Don't know if there is another bill that has any many signers/co-sponsors/whatever they call it, so hopefully it happens.  

SD, good question. No question that I am somewhat unhappy/frustrated about PFE's price movement.

First let me say that I don't know what is really going on behind the scenes with Starboard, Bourla, and others in the boardroom, so I will confine my thoughts to other things. I will give an example at the end of this but no question PFE is out of favor with investors and that is also partly because many are chasing momentum stocks. Like you say, they had great earnings this past qtr and the next qtr will be great in comparison to the same qtr last year. They have been cutting expenses, which is good and have almost 60 drugs in either phase II or phase III trials. No question I should have taken some or all off the table when they hit $60 almost exactly 3 years ago, but dumb me.

In Feb, Mar, April of this year I bought BMY in the high 40's and low 50's. It proceeded to go down (looking like another PFE) and in July I bought more at $40. Well, BMY has turned it around in the last month and today, after ABBV announced that their schizo drug missed targets, the stock jumped to $60. For quite a while things looked just as dire for BMY. I guess my experience with BMY this year has not only given me hope for the future of PFE but kept me calm while watching it go down. So, right now, I am sticking with PFE (and sucking up the divvy in the meantime) assuming and thinking that its time will come. With all those drugs in trials some have to hit just as some will fail.

When I look at my Fidelity site and the research section on PFE I see most if not all analysts rating it highly (that does scare me a tiny bit) and they have a thing called Trefis Valuation Estimate (have no idea what that is) and it pegs fair value at this very instant at $36.22. That is about $10 higher than the stock closed today. I don't presume to know how to unlock the value there, but I definitely think there is more value in the company than $26 a share. Plus if we expect interest rates to continue to come down the 6%+ div should ultimately drive investors looking for yield into the stock. Hope this didn't sound to rosy. I guess you didn't catch me on a bad day. Are your thoughts on PFE much different?

Not that I'm aware. Do know we have ability in ghat regard since we have huge margins.  Maybe the focus is so much on selling the company that they don't want to fiddle with that. 

Yes it has looked like Powell is developing a spine (although he did cave during Trump's first term and may yet again) but saw story this morning Musk and others pushing to have Fed under control of Pres:

https://nypost.com/2024/11/11/business/elon-musk-backs-call-to-place-fed-under-trumps-control/


Hopefully with workforce reduction and Tang onboard we can get Auphie moving and sold before Vera enters the scene. 

I guess those betting on acceptance had all piled in before today, so no more buying pressure. Have to see how the next few days shake out.  

Curious to hear what they have to say at the Investors' Conference.  Better hear something new.  

Other than passage of the Kidney Act I should say. 

I guess this acceptance was built-in by the rise from 25 cents to 60 cents.  Not sure what other catalyst can get us to a buck?

Well put

Tanking again this morning possibly because UNCY's drug got accepted for review by FDA

Thanks for posting.  Saw that a few min ago.  However it doesn't yet seem to be moving the stock in pm yet.  News not reached enough people?   

Thanks Kiwi. Guess I was theown off by the term "small" rather than the usual %.  Made me think it was in a spot that was too narrow or small for a stent, but you cleared that up.  

Of course here in the US a decision on CAGB  is many times determined by gge type of insurance, or absence of it, the patient has.  

Thanks for posting this from Australia. One thing caught my eye and that was the comment that the blockage was too small for stents and only option was conservative management. I wonder why CAGB was not an option, not that I would want that but just wondering why that was not an option.

Yep, best healthcare that lobbyists' money can buy. 

Stocktwits is a fire over this post:

https://x.com/tonkhalife/status/1855663911237747004?s=46&t=VJb6Ff31iAXg1p7xDcqPUQ

Thanks for posting.  The more pressure put on Congress the better chance (never great) that the Kidney Act gets passed.  All it takes though is someone with a wild hair up their arse to block the thing. 

Happened to me this past week.  The House was set to vote on eliminating WEP for SS, and 2 from the Freedom Caucus put a block.  Last I heard, upset so many that Johnson promises to bring it to a vote this week. Shall see. 

Sleven, sure. Of course companies and people have ways to get around problems like that. If not, your supposition is correct that the cost may increase.

Sure seems like a bunch of late. Hard to imagine the Generics claiming they are locked out of supply, because I doubt Amarin is using all of this.